{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:25:51Z","timestamp":1773231951339,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12020000"],"award-info":[{"award-number":["XDA12020000"]}]},{"DOI":"10.13039\/501100013143","name":"NSFC-Shandong Joint Fund for Marine Science Research Centers","doi-asserted-by":"crossref","award":["U1406402"],"award-info":[{"award-number":["U1406402"]}],"id":[{"id":"10.13039\/501100013143","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81302791"],"award-info":[{"award-number":["81302791"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Youth Innovation Promotion Association CAS, Shanghai Talent Development Funds","award":["201663"],"award-info":[{"award-number":["201663"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDA12020326"],"award-info":[{"award-number":["XDA12020326"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.canlet.2017.06.029","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T01:15:21Z","timestamp":1499217321000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition"],"prefix":"10.1016","volume":"406","author":[{"given":"Danni","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.06.029_bib1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2011.289","article-title":"Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?","volume":"105","author":"Langley","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2017.06.029_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2017.06.029_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-13-1573","article-title":"NSAIDs inhibit tumorigenesis, but how?","volume":"20","author":"Gurpinar","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.06.029_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00181","article-title":"COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs","volume":"3","author":"Gurpinar","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2017.06.029_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10555-011-9301-4","article-title":"COX inhibitors directly alter gene expression: role in cancer prevention?","volume":"30","author":"Wang","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2017.06.029_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2017.06.029_bib7","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.274.38.27307","article-title":"Sulindac inhibits activation of the NF-kappaB pathway","volume":"274","author":"Yamamoto","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.06.029_bib8","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1038\/sj.onc.1209658","article-title":"Effect of aspirin on the Wnt\/beta-catenin pathway is mediated via protein phosphatase 2A","volume":"25","author":"Bos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2017.06.029_bib9","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2017.06.029_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbrc.2011.04.027","article-title":"Aspirin-induced AMP-activated protein kinase activation regulates the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats","volume":"408","author":"Sung","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2017.06.029_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase,","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.canlet.2017.06.029_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2017.06.029_bib13","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2017.06.029_bib14","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.2013.6599","article-title":"Aspirin use and risk of colorectal cancer according to BRAF mutation status","volume":"309","author":"Nishihara","year":"2013","journal-title":"Jama-J Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2017.06.029_bib15","doi-asserted-by":"crossref","first-page":"21208","DOI":"10.18632\/oncotarget.4126","article-title":"Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in\u00a0vitro and in\u00a0vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2","volume":"6","author":"Yue","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.06.029_bib16","first-page":"219","article-title":"Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells","volume":"20","author":"Sonnemann","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2017.06.029_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcmm.12461","article-title":"Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737","volume":"19","author":"Zhang","year":"2015","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.canlet.2017.06.029_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib20","first-page":"5","article-title":"TOR signaling in growth and metabolism","volume":"127","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2017.06.029_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.canlet.2017.06.029_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bcp.2012.01.019","article-title":"Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR","volume":"83","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2017.06.029_bib25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Gene Dev."},{"key":"10.1016\/j.canlet.2017.06.029_bib26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1,","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2017.06.029_bib27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"G\u00a0beta L, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR","volume":"11","author":"Kim","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2017.06.029_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2013.08.046","article-title":"Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer","volume":"342","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2017.06.029_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.06.029_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2017.06.029_bib34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","article-title":"Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in\u00a0vivo","volume":"51","author":"Newell","year":"2009","journal-title":"J.\u00a0hepatology"},{"key":"10.1016\/j.canlet.2017.06.029_bib35","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-07-4774","article-title":"Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.06.029_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell metab."},{"key":"10.1016\/j.canlet.2017.06.029_bib37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/(SICI)1097-0215(19971210)73:6<880::AID-IJC20>3.0.CO;2-7","article-title":"Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells","volume":"73","author":"Ricchi","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2017.06.029_bib38","doi-asserted-by":"crossref","first-page":"39505","DOI":"10.1074\/jbc.M506096200","article-title":"Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex","volume":"280","author":"Sarbassov","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.06.029_bib39","doi-asserted-by":"crossref","first-page":"18717","DOI":"10.1074\/jbc.M414499200","article-title":"The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses","volume":"280","author":"Smith","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.06.029_bib40","first-page":"1249","article-title":"Colorectal cancer and aspirin: significantly diverse results influenced by the cancer's BRAF-mutation status","volume":"14","author":"Galukande","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.canlet.2017.06.029_bib41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2017.06.029_bib42","first-page":"4951","article-title":"PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras\/Raf\/MAPK and PI3K\/AKT\/mTOR pathways","volume":"30","author":"Gedaly","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2017.06.029_bib43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","article-title":"Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma","volume":"13","author":"Zhai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.06.029_bib44","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"Foster","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.06.029_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004632","article-title":"mTORC1 status dictates tumor response to targeted therapeutics","volume":"6","author":"Kelsey","year":"2013","journal-title":"Sci. Signal"},{"key":"10.1016\/j.canlet.2017.06.029_bib46","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00280-013-2118-9","article-title":"Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors","volume":"71","author":"Chan","year":"2013","journal-title":"Cancer Chemoth Pharm."},{"key":"10.1016\/j.canlet.2017.06.029_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.2545","article-title":"A\u00a0drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies","volume":"26","author":"Gangadhar","year":"2008","journal-title":"J.\u00a0Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517304111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517304111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T01:44:09Z","timestamp":1589766249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517304111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"alternative-id":["S0304383517304111"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.06.029","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}